Taken together, the current data suggest that high CD82 expression blocks fibronectin adhesion-induced EMT in prostate cancer cells through the repression of associated α3β1/α5β1 integrin-mediated signaling events. This evidence concerns the gene CD82 and prostate carcinoma.